The estimated Net Worth of Jeffrey Stuart Peters is at least 1.22 百万$ dollars as of 6 March 2024. Mr Peters owns over 19,625 units of Macrogenics Inc stock worth over 103,242$ and over the last 7 years he sold MGNX stock worth over 1,117,341$.
Mr has made over 11 trades of the Macrogenics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 51,395 units of MGNX stock worth 799,192$ on 4 April 2024.
The largest trade he's ever made was exercising 76,251 units of Macrogenics Inc stock on 5 February 2024 worth over 847,149$. On average, Mr trades about 13,285 units every 105 days since 2018. As of 6 March 2024 he still owns at least 28,520 units of Macrogenics Inc stock.
You can see the complete history of Mr Peters stock trades at the bottom of the page.
Jeffrey Stuart Peters is the Sr. VP & Gen. Counsel at Macrogenics Inc.
Mr Peters is 49, he's been the Sr. VP & Gen. Counsel of Macrogenics Inc since . There are 8 older and 1 younger executives at Macrogenics Inc. The oldest executive at Macrogenics Inc is Dr. Scott Koenig M.D., Ph.D., 69, who is the CEO, Pres & Director.
Over the last 11 years, insiders at Macrogenics Inc have traded over 27,036,278$ worth of Macrogenics Inc stock and bought 4,026,274 units worth 39,875,062$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Target N Vbb Biotech Ag Bio...、Edward Hurwitz. On average, Macrogenics Inc executives and independent directors trade stock every 21 days with the average trade being worth of 132,068$. The most recent stock trade was executed by Jay Philip Siegel on 20 May 2024, trading 4,500 units of MGNX stock currently worth 16,290$.
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Macrogenics Inc executives and other stock owners filed with the SEC include: